Legend ® Multi Dose (hyaluronate sodium) Injectable Solution

Manufacturer
Boehringer Ingelheim Animal Health USA Inc.
Effective date
2025-05-02
Label type
PRESCRIPTION ANIMAL DRUG LABEL
Version
2
Source
full-release
Hydrated at
2026-06-01 02:44:36

Label at a glance#

ProductLegend Multi Dose
Active ingredienthyaluronate sodium
Label structure21 sections

Storage and handling

STORAGE: Store at or below 77°F (25°C). Brief excursions to 104°F (40°C) are permitted. Discard remaining product 6 months after first use.

Label contents#

Full prescribing information#

SPL UNCLASSIFIED SECTION

For intravenous use in horses only

Not for intra-articular use

20 mL

SPL UNCLASSIFIED SECTION

CAUTION:

Federal law restricts this drug to use by or on the order of a licensed veterinarian.

DESCRIPTION SECTION

DESCRIPTION:

LEGEND Multi Dose Injectable Solution is a clear, colorless solution of low viscosity. LEGEND Multi Dose Injectable Solution is pyrogen free and sterile. It is administered by intravenous injection.

Hyaluronic acid, the conjugate acid of hyaluronate sodium, is extracted from the capsule of Streptococcus spp. and purified, resulting in a form which is essentially free of protein and nucleic acids.

LEGEND Multi Dose Injectable Solution is supplied in 20 mL vials. Each mL contains 10 mg hyaluronate sodium, 8.5 mg sodium chloride, 0.223 mg sodium phosphate dibasic, 0.04 mg sodium phosphate monobasic and 15.63 mg benzyl alcohol as a preservative. The pH is adjusted to between 6.5 and 8.0 with sodium hydroxide or hydrochloric acid.

SPL UNCLASSIFIED SECTION

CHEMISTRY:

Hyaluronic acid, a glycosaminoglycan, can exist in the following forms depending upon the chemical environment in which it is found: as the acid, hyaluronic acid; as the sodium salt, sodium hyaluronate (hyaluronate sodium); or as the hyaluronate anion. These terms may be used interchangeably but in all cases, reference is made to the glycosaminoglycan composed of repeating subunits of D-glucuronic acid and N-acetyl-D-glucosamine linked together by glycosidic bonds. Since this product originates from a microbial source, there is no potential for contamination with dermatan or chondroitin sulfate or any other glycosaminoglycan.

CLINICAL PHARMACOLOGY SECTION

CLINICAL PHARMACOLOGY:

Hyaluronic acid is a naturally occurring substance present in connective tissue, skin, vitreous humour and the umbilical cord in all mammals. High concentrations of hyaluronic acid are also found in the synovial fluid. It also constitutes the major component of the capsule of certain microorganisms. The hyaluronic acid produced by bacteria is of the same structure and configuration as that found in mammals.

The actual mechanism of action for hyaluronate sodium in the healing of degenerative joint disease is not completely understood. One major function appears to be the regulation of normal cellular constituents. This effect decreases the impact of exudation, enzyme release and subsequent degradation of joint integrity. Additionally, hyaluronate sodium exerts an anti-inflammatory action by inhibiting the movement of granulocytes and macrophages.1 Hyaluronate molecules are long chains which form a filter network interspersed with normal cellular fluids.

VETERINARY INDICATIONS SECTION

INDICATIONS:

LEGEND Multi Dose Injectable Solution is indicated in the treatment of joint dysfunction of the carpus or fetlock in horses due to non-infectious synovitis associated with equine osteoarthritis.

DOSAGE & ADMINISTRATION SECTION

DOSAGE AND ADMINISTRATION:

4 mL (40 mg) injected intravenously. Treatment may be repeated at weekly intervals for a total of three treatments.

Use aseptic technique and inject slowly into the jugular vein.

Horses should be given stall rest after treatment before gradually resuming normal activity.

CONTRAINDICATIONS SECTION

CONTRAINDICATIONS:

There are no known contraindications for the use of LEGEND Multi Dose Injectable Solution in horses.

RESIDUE WARNING SECTION

RESIDUE WARNING:

Do not use in horses intended for human consumption.

WARNINGS SECTION

HUMAN WARNINGS:

Not for use in humans. Keep this and all other drugs out of reach of children.

SPL UNCLASSIFIED SECTION

ANIMAL SAFETY WARNINGS:

Not for Intra-articular use. The Intra-articular safety of hyaluronate sodium with benzyl alcohol has not been evaluated.

PRECAUTIONS SECTION

PRECAUTIONS:

Radiographic evaluation should be carried out in cases of acute lameness to ensure that the joint is free from serious fracture.

The safety of LEGEND Multi Dose Injectable Solution has not been evaluated in breeding stallions or in breeding, pregnant or lactating mares.

ADVERSE REACTIONS SECTION

ADVERSE REACTIONS:

No local or systemic side effects were observed in the field studies using LEGEND Injectable Solution.

SPL UNCLASSIFIED SECTION

Post-Approval Experience: While all adverse reactions are not reported, the following adverse reactions are based on voluntary post-approval reporting for LEGEND Injectable Solution: Occasional depression, lethargy, and fever.

To report suspected adverse events, for technical assistance or to obtain a copy of the Safety Data Sheet (SDS), contact Boehringer Ingelheim Animal Health USA Inc. at 1-888-637-4251. For additional information about adverse drug experience reporting for animal drugs, contact FDA at 1-888-FDA-VETS or online at www.fda.gov/reportanimalae.

SPL UNCLASSIFIED SECTION

EFFECTIVENESS:

Effectiveness studies utilizing LEGEND Multi Dose Injectable Solution were not performed. LEGEND Multi Dose Injectable Solution was approved based on the conclusion that the effectiveness of LEGEND Multi Dose Injectable Solution will not differ from that demonstrated for the original formulation of LEGEND Injectable Solution.

Twenty-one horses with lameness in either the carpal or fetlock joints were treated intravenously with LEGEND Injectable Solution in a well-controlled field study conducted at four locations. One, two or three injections were given based on clinical improvement. Overall clinical improvement was judged as excellent or good in 90% of the cases treated intravenously with LEGEND Injectable Solution.

SPL UNCLASSIFIED SECTION

ANIMAL SAFETY:

Animal safety studies utilizing LEGEND Multi Dose Injectable Solution were not performed. LEGEND Multi Dose Injectable Solution was approved based on the conclusion that the safety of LEGEND Multi Dose Injectable Solution will not differ from that demonstrated for the original formulation of LEGEND Injectable Solution.

LEGEND Injectable Solution was administered to normal horses at one, three and five times the recommended intravenous dosage of 40 mg. Treatments were given once weekly for nine consecutive weeks (three times the maximum duration). No systemic clinical signs were observed nor were there any adverse effects upon hematology or clinical chemistry parameters.

STORAGE AND HANDLING SECTION

STORAGE:

Store at or below 77°F (25°C). Brief excursions to 104°F (40°C) are permitted. Discard remaining product 6 months after first use.

HOW SUPPLIED SECTION

HOW SUPPLIED:

LEGEND Multi Dose Injectable Solution is supplied in 20 mL bottles.

SPL UNCLASSIFIED SECTION

Approved by FDA under NADA # 140-883

Marketed by: Boehringer Ingelheim Animal Health USA Inc., Duluth, GA 30096

REFERENCES SECTION

REFERENCE:

1Swanstrom, O.G. 1978. Hyaluronate (hyaluronic acid) and its use, Proc. American Assoc. Equine Pract., 24th annual convention, pp. 345-348.

SPL UNCLASSIFIED SECTION

®LEGEND is a registered trademark and the horse logo is a trademark of Boehringer Ingelheim Animal Health USA Inc.
©2019 Boehringer Ingelheim Animal Health USA Inc.

1050-8683-03, Rev. 12-2019 86851121

PRINCIPAL DISPLAY PANEL - 20 mL Bottle Carton

PACKAGE LABEL.PRINCIPAL DISPLAY PANEL

Legend® Multi Dose
(hyaluronate sodium)
Injectable Solution 10 mg/mL

For intravenous use in horses only
Not for intra-articular use

1 x 20 mL vial

CAUTION: Federal law restricts this drug to use by or on the order of a licensed veterinarian.

Approved by FDA under NADA # 140-883

Picture of 20 mL display carton
Picture of 20 mL display carton

DailyMed RxNorm Mappings#

RxCUI, RxNorm string, TTY table
RxCUIRxNorm stringTTYSPL version
891140Legend 10 MG/ML Injectable SolutionPSN2
562106sodium hyaluronate 10 MG/mL Injectable SolutionPSN2
891140sodium hyaluronate 10 MG/ML Injectable Solution [Legend]SBD2
562106sodium hyaluronate 10 MG/ML Injectable SolutionSCD2
891140Legend 10 MG/ML Injectable SolutionSY2
891140Legend 20 MG per 2 ML Injectable SolutionSY2
891140Legend 40 MG per 4 ML Injectable SolutionSY2

DailyMed Package Descriptions#

Package NDC, Product, Description table
Package NDCProductDescriptionFormQuantityStrengthSPL version
0010-3142-01Legend Multi Dose1 in 1 CARTONINJECTION, SOLUTION12
0010-3142-01Legend Multi Dose20 mL in 1 BOTTLEINJECTION, SOLUTION202

DailyMed Dashboard NDC Coverage#

NDC, Dashboard title, SPL version table
NDCDashboard titleSPL versionValidationDashboard ZIP
0010-3142LEGEND MULTI DOSE (HYALURONATE SODIUM) INJECTION, SOLUTION [BOEHRINGER INGELHEIM ANIMAL HEALTH USA INC.]22 package rows20250504_88a65861-b189-4d3c-9752-bdb6ce0dc916.zip

Products#

Every source-derived product name is available through these pages.

DailyMed product names page 1 of 1 · 7 matching rows.

NDC Codes#

Product NDC, Package NDC table
Product NDCPackage NDC
0010-31420010-3142-01

Ingredients#

Every source-derived ingredient row is available through these pages.

DailyMed ingredient rows page 1 of 1 · 5 matching rows.

Source Document#

Source XML

openFDA label cross-check#

OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.

Matched openFDA labels page 1 of 1 · 1 matching rows.

Brand, Generic, Manufacturer table
BrandGenericManufacturerSPL set IDEffective dateAvailable safety fieldsJoin
CELISTAR MICRONEEDLING INFUSIONHYALURONATE SODIUMGuangdong Outeli Biotechnology Co., Ltd.53de46a7-3947-70a7-e063-6294a90ab8292026-06-09WarningsName fallback
generic name: HYALURONATE SODIUM

Reported adverse events (FAERS/openFDA)#

Adverse event summaries are temporarily unavailable. Other product information remains available.